company insight

Pharma Support Services Ltd  - your regulatory and pharmaco vigilance provider in Eastern Europe

Achieving compliance with local requirements can be a tough deal and an unexpected challenge sometimes -

Achieving compliance with local requirements can be a tough deal and an unexpected challenge sometimes

Hence you need a partner you can trust

Given the diversity of the Eastern European region and the fact that the languages spoken are very different from one another (as both Cyrillic and Latin alphabets are used in the region dependent on the country) launching your products can be a challenge. It needs to be matched with a local expertise in regulatory affairs, pharmacovigilance and pricing - all of which are essentials for speedy access to Eastern European markets. Whether you are only exploring possibilities to expand or already have presence in Eastern Europe we can adapt our services to be of help to your business.

As a first prerequisite we ensure you receive a well-grounded legal advice and country-specific background. Based in Sofia, Bulgaria and having reliable partners all over Eastern Europe, we can find the right partner for you should you be looking for a GMP, GDP compliant warehouse or support with medical devices and medicinal products registration and their pricing and reimbursement possibilities. As the healthcare systems in many of the countries in the region are based on the so-called „external reference pricing system“ we can provide guidance on which countries are included in the reference basket and what strategy can be adopted to secure your product on the market.  

we can find the right partner for you should you be looking for a GMP

Worried about Brexit outcome?

Further down the line of establishing in your business in Eastern Europe we are happy to support you with transfer of marketing authorisations, finalization of national phases of your DCP/MRP applications as well as start a national authorisation procedure for your product, should you be interested in one market only. We have a broad expertise in registration and communication of all necessary requirements so that you can focus on marketing your products while we do the rest.

In addition to local pharmacovigilance point of contact as well as literature screening of non-indexed journals and publications we perform follow-up assessment of relevant articles/scientific extracts. Medical review of cases published in literature can help you identify important signals concerning the safety profile of your products. And a lot of locally issued journals are not indexed by Embase and Medline, so we can provide further assistance with these issues.

Share this article

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue